Sodium hydrosulfide has no additive effects on nitrite-inhibited renal gluconeogenesis in type 2 diabetic rats

Jeddi, Sajad; Gheibi, Sevda; Kashfi, Khosrow; Ghasemi, Asghar

doi:10.1016/j.lfs.2021.119870

Cited by 4 publications

(1 citation statement)

References 75 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This non-obese type 2 diabetes animal model was initially established in rats [ 24 ] but has since been extended to include mice with modifications of the original protocol. In comparison with the high-fat-diet (HFD)-STZ-induced type 2 diabetes animal models [ 25 , 26 , 27 , 28 ] and genetically engineered diabetic animal models, such as db/db mice [ 29 ] and zsf1 obese rats [ 30 ], the NA/STZ model is time-saving and less expensive. Therefore, this model can be equally used as a platform for not only exploring the pathogenesis of DN but also screening and testing potential antidiabetic agents [ 31 ] or renoprotective compounds for their therapeutic effects [ 21 ].…”

Section: Introductionmentioning

confidence: 99%

The Nicotinamide/Streptozotocin Rodent Model of Type 2 Diabetes: Renal Pathophysiology and Redox Imbalance Features

2022

Biomolecules

View full text Add to dashboard Cite

Diabetic nephropathy (DN) is a common complication of diabetes mellitus. While there has been a great advance in our understanding of the pathogenesis of DN, no effective managements of this chronic kidney disease are currently available. Therefore, continuing to elucidate the underlying biochemical and molecular mechanisms of DN remains a constant need. In this regard, animal models of diabetes are indispensable tools. This review article highlights a widely used rodent model of non-obese type 2 diabetes induced by nicotinamide (NA) and streptozotocin (STZ). The mechanism underlying diabetes induction by combining the two chemicals involves blunting the toxic effect of STZ by NA so that only a percentage of β cells are destroyed and the remaining viable β cells can still respond to glucose stimulation. This NA-STZ animal model, as a platform for the testing of numerous antidiabetic and renoprotective materials, is also discussed. In comparison with other type 2 diabetic animal models, such as high-fat-diet/STZ models and genetically engineered rodent models, the NA-STZ model is non-obese and is less time-consuming and less expensive to create. Given that this unique model mimics certain pathological features of human DN, this model should continue to find its applications in the field of diabetes research.

show abstract